Abstract
Objectives To evaluate efficacy and safety of citalopram in the treatment of depression of cancer patients. Methods In the 6-week, randomized, double-blind and parallel controlled clinical trial, 188 patients were randomly divided into citalopram group and placebo group. All the patients were assessed with HAMD-17, HAMA before treatment and after 1, 2, 4 and 6 weeks of treatment.Safety measures included adverse reactions observation. Results The total effective rates of the escitalopram group 62.22％. The scores of HAMD 17 and HAMA in citalopram decreased significantly,with statistically difference compared with the baseline and placebo group. Conclutions Citalopram is an effective and safety antidepressant treatment to depression in cancer patients. Key words: Citalopram; Depression; Cancer; Randomized controlled trials
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
